JP2019531743A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531743A5 JP2019531743A5 JP2019520742A JP2019520742A JP2019531743A5 JP 2019531743 A5 JP2019531743 A5 JP 2019531743A5 JP 2019520742 A JP2019520742 A JP 2019520742A JP 2019520742 A JP2019520742 A JP 2019520742A JP 2019531743 A5 JP2019531743 A5 JP 2019531743A5
- Authority
- JP
- Japan
- Prior art keywords
- endogenous
- cell
- immune cells
- immune
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002865 immune cell Anatomy 0.000 claims 25
- 238000000034 method Methods 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 7
- 102100038077 CD226 antigen Human genes 0.000 claims 4
- 108091026890 Coding region Proteins 0.000 claims 4
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- -1 Itga6 Proteins 0.000 claims 4
- 102100033447 T-lymphocyte surface antigen Ly-9 Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000005931 immune cell recruitment Effects 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 210000000822 natural killer cell Anatomy 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims 2
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims 2
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims 2
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 2
- 101001018021 Homo sapiens T-lymphocyte surface antigen Ly-9 Proteins 0.000 claims 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims 2
- 102100033467 L-selectin Human genes 0.000 claims 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 2
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 2
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 2
- 101710114141 T-lymphocyte surface antigen Ly-9 Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000002688 persistence Effects 0.000 claims 2
- 108091033319 polynucleotide Chemical group 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Chemical group 0.000 claims 2
- 210000004986 primary T-cell Anatomy 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 2
- 230000003248 secreting effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 230000002103 transcriptional effect Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 101150043532 CISH gene Proteins 0.000 claims 1
- 101150008702 CRABP2 gene Proteins 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010048623 Collagen Receptors Proteins 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 claims 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 claims 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 claims 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 claims 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 claims 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 102100031780 Endonuclease Human genes 0.000 claims 1
- 108010042407 Endonucleases Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101150063370 Gzmb gene Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 claims 1
- 101000589301 Homo sapiens Natural cytotoxicity triggering receptor 1 Proteins 0.000 claims 1
- 101000589307 Homo sapiens Natural cytotoxicity triggering receptor 3 Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 102100025305 Integrin alpha-2 Human genes 0.000 claims 1
- 102000000507 Integrin alpha2 Human genes 0.000 claims 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102100030704 Interleukin-21 Human genes 0.000 claims 1
- 101150069255 KLRC1 gene Proteins 0.000 claims 1
- 108010092694 L-Selectin Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims 1
- 101100005692 Mus musculus Cd1d1 gene Proteins 0.000 claims 1
- 101100176487 Mus musculus Gzmc gene Proteins 0.000 claims 1
- 101100341507 Mus musculus Itgae gene Proteins 0.000 claims 1
- 101100236066 Mus musculus Lilrb4b gene Proteins 0.000 claims 1
- 101100369641 Mus musculus Tigit gene Proteins 0.000 claims 1
- 101150026563 NR4A2 gene Proteins 0.000 claims 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 1
- 108050003738 Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101150075616 Nr4a3 gene Proteins 0.000 claims 1
- 101150065603 PLEK gene Proteins 0.000 claims 1
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 claims 1
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 101100005696 Rattus norvegicus Cd1d gene Proteins 0.000 claims 1
- 101150051144 Rcbtb2 gene Proteins 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 101150060512 SPATA6 gene Proteins 0.000 claims 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 101150040313 Wee1 gene Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 101150113535 chek1 gene Proteins 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 229960002986 dinoprostone Drugs 0.000 claims 1
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 108040006870 interleukin-10 receptor activity proteins Proteins 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000003334 potential effect Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410187P | 2016-10-19 | 2016-10-19 | |
| US62/410,187 | 2016-10-19 | ||
| DKPA201670840 | 2016-10-27 | ||
| DKPA201670840 | 2016-10-27 | ||
| PCT/EP2017/076798 WO2018073391A1 (en) | 2016-10-19 | 2017-10-19 | Targeted gene insertion for improved immune cells therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531743A JP2019531743A (ja) | 2019-11-07 |
| JP2019531743A5 true JP2019531743A5 (enExample) | 2020-11-12 |
| JP7274416B2 JP7274416B2 (ja) | 2023-05-16 |
Family
ID=60268351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520742A Active JP7274416B2 (ja) | 2016-10-19 | 2017-10-19 | 改善された免疫細胞療法のための標的指向遺伝子挿入 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11873511B2 (enExample) |
| EP (1) | EP3529351A1 (enExample) |
| JP (1) | JP7274416B2 (enExample) |
| KR (1) | KR102709329B1 (enExample) |
| CN (1) | CN110023490B (enExample) |
| AU (1) | AU2017347637B2 (enExample) |
| BR (1) | BR112019007715A2 (enExample) |
| CA (1) | CA3040048A1 (enExample) |
| IL (1) | IL265953A (enExample) |
| MX (1) | MX2019004215A (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018001232A2 (pt) | 2015-07-21 | 2018-09-25 | The Children's Medical Center Corporation | pd-l1 que expressa células-tronco hematopoéticas e usos |
| WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
| CN110841058B (zh) * | 2019-11-21 | 2022-09-02 | 北京启辰生生物科技有限公司 | 用于协同改善免疫应答的组合物及应用 |
| CN110790842B (zh) * | 2019-11-25 | 2021-03-30 | 贵州康钦承平生物科技有限公司 | 一种FasL-CAR融合蛋白和表达融合蛋白的T细胞及其制备方法和应用 |
| EP4171616A1 (en) * | 2020-06-26 | 2023-05-03 | Juno Therapeutics GmbH | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| KR102491095B1 (ko) * | 2021-01-22 | 2023-01-20 | 한국생명공학연구원 | Cas 단백질 및 HIF의 TAD 도메인을 포함하는 단백질 융합체 및 이의 용도 |
| KR102500873B1 (ko) * | 2021-02-03 | 2023-02-17 | 한국과학기술연구원 | 자연살해세포 특이적 CRISPR/Cas 시스템을 위한 융합 단백질 및 이의 용도 |
| US20230016422A1 (en) * | 2021-06-23 | 2023-01-19 | Crispr Therapeutics Ag | Engineered cells with improved protection from natural killer cell killing |
| CN113604437A (zh) * | 2021-08-13 | 2021-11-05 | 青岛华赛伯曼医学细胞生物有限公司 | 过表达ccr2的免疫细胞及其应用 |
| CN118234851A (zh) * | 2021-11-19 | 2024-06-21 | 南开大学 | 重组武装溶瘤病毒组合物及其在til过继治疗中的用途 |
| WO2024022509A1 (en) * | 2022-07-29 | 2024-02-01 | Nanjing Legend Biotech Co., Ltd. | Methods for promoting persistence of cell therapy |
| CN115820697B (zh) * | 2022-09-23 | 2024-07-30 | 中国海洋大学 | 一种免疫细胞及其制备方法和应用 |
| CN115286697B (zh) * | 2022-09-29 | 2022-12-13 | 烟台蓝纳成生物技术有限公司 | 一种双重靶向化合物及其制备方法和应用 |
| CN115851909B (zh) * | 2022-11-21 | 2023-09-08 | 郑州大学第一附属医院 | 检测fosb基因的试剂在制备诊断腹主动脉瘤产品的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3133545C (en) * | 2012-05-25 | 2023-08-08 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| AU2014266833B2 (en) * | 2013-05-13 | 2020-07-02 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| DK3004337T3 (da) | 2013-05-29 | 2017-11-13 | Cellectis | Fremgangsmåde til konstruktion af T-celler til immunoterapi ved brug af RNA-guidet Cas nuklease-system |
| WO2015075195A1 (en) | 2013-11-22 | 2015-05-28 | Cellectis | Method of engineering chemotherapy drug resistant t-cells for immunotherapy |
| ES2782125T3 (es) | 2014-03-11 | 2020-09-10 | Cellectis | Método para generar linfocitos T compatibles para trasplante alogénico |
| AU2016214301B2 (en) | 2015-02-06 | 2022-05-19 | Cellectis | Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles |
| BR112017020750A2 (pt) | 2015-03-27 | 2018-06-26 | Harvard College | células t modificadas e métodos de produção e utilização das mesmas |
| GB2557123B (en) * | 2015-07-31 | 2021-11-03 | Univ Minnesota | Modified cells and methods of therapy |
| CA3020923A1 (en) | 2016-04-15 | 2017-10-19 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
-
2017
- 2017-10-19 AU AU2017347637A patent/AU2017347637B2/en active Active
- 2017-10-19 EP EP17794689.4A patent/EP3529351A1/en active Pending
- 2017-10-19 CA CA3040048A patent/CA3040048A1/en active Pending
- 2017-10-19 BR BR112019007715A patent/BR112019007715A2/pt unknown
- 2017-10-19 JP JP2019520742A patent/JP7274416B2/ja active Active
- 2017-10-19 US US16/340,222 patent/US11873511B2/en active Active
- 2017-10-19 CN CN201780072672.5A patent/CN110023490B/zh active Active
- 2017-10-19 MX MX2019004215A patent/MX2019004215A/es unknown
- 2017-10-19 KR KR1020197013626A patent/KR102709329B1/ko active Active
-
2019
- 2019-04-10 IL IL265953A patent/IL265953A/en unknown
-
2023
- 2023-12-14 US US18/540,309 patent/US12391933B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531743A5 (enExample) | ||
| US12391933B2 (en) | Targeted gene insertion for improved immune cells therapy | |
| US12209125B2 (en) | Targeted gene integration of NK inhibitors genes for improved immune cells therapy | |
| US11834502B2 (en) | Reducing immune inhibition induced by SIGLEC-15 | |
| CA3151690A1 (en) | Genetically-edited immune cells and methods of therapy | |
| WO2018073391A1 (en) | Targeted gene insertion for improved immune cells therapy | |
| US20220105134A1 (en) | Modified cell and use thereof in gene and cell therapy | |
| WO2019025800A1 (en) | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE | |
| Van Caeneghem et al. | Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities | |
| US20190290694A1 (en) | Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy | |
| WO2018115189A1 (en) | Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy | |
| US11788072B2 (en) | Activation of APC in immunotherapy | |
| CN110819596B (zh) | 具有增强的迁移能力的修饰的细胞 | |
| US20240075061A1 (en) | Cell therapy activating lymphocyte in tme | |
| AU2023291806A1 (en) | Method for expanding immune cells | |
| WO2023242426A1 (en) | Method for expanding immune cells | |
| WO2024256627A1 (en) | Novel innate lymphoid cells (ilcs) | |
| CN120091826A (zh) | 多发性硬化症的细胞疗法 | |
| Dahiya et al. | Genome Engineering Tools in Immunotherapy | |
| Hu et al. | Donor Natural Killer Cells and Their Therapeutic Potential in Allogeneic Hematopoietic Stem Cell | |
| June | Cell therapy for cancer–our synthetic future | |
| Lee et al. | Nk-cell immunotherapy for aml |